Fifty-three and a half, she says
Unlock Exclusive Market InsightsDownload the Brochure Now and Dive Deeper into the Future of the Global Glucagon-Like Peptide-1 Agonists Market
Current evidence from large-scale clinical trials and meta-analyses does not establish a causal link between GLP-1-based therapies and increased overall cancer risk in humans
oral administration and low incidence of hypoglycemia are important advantages
In pre-specified analyses for time to first occurrence of MACE, there were 44 MACE-5 (all-cause death, heart attack, stroke, heart failure event, or coronary revascularization ) events observed in participants randomized to retatrutide (pooled 9 mg and 12 mg) and 52 events observed in those randomized to placebo, resulting in a hazard ratio of 0.82 (95.0% CI: 0.55 to 1.22)
Sodum, N., Mattila, O., Sharma, R., Kamakura, R., Lehto, V